Drugmakers delay in-demand medicines to evade Biden's new pricing rules | Business

Drugmakers are slow-walking products to market to get around President Joe Biden’s plan to lower medication prices.

Related Keywords

United States ,Americans ,David Epstein ,Duane Wright ,Cheryl Herbert ,Joe Biden ,Sanjiv Patel ,Leigh Purvis ,Scott Gottlieb ,Alnylam Pharmaceuticals Inc ,Us House Committee On Oversight ,Astellas Pharma Inc ,Abbvie Inc ,Enterprise Associates ,Drug Administration ,Relay Therapeutics Inc ,Pfizer ,Congressional Budget Office ,Pfizer Inc ,Roche Holding ,National Organization For Rare Disorders ,President Joe Biden ,Alnylam Pharmaceuticals ,Inflation Reduction Act ,Bloomberg Intelligence ,New Enterprise Associates ,Relay Therapeutics ,Executive Officer Sanjiv Patel ,Vital Transformation ,National Organization ,Nation And World ,Op Stories ,Health Matters ,Business ,